{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:13:57Z","timestamp":1792782837112,"version":"4.5.0"},"reference-count":143,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:00:00Z","timestamp":1788998400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:00:00Z","timestamp":1788998400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"University of Innsbruck and Medical University of Innsbruck","id":[{"id":"https:\/\/ror.org\/054pv6659","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Biol Inorg Chem"],"DOI":"10.1007\/s00775-026-02172-x","type":"journal-article","created":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T14:20:33Z","timestamp":1789050033000},"page":"469-488","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Current clinical applications and future developments of platinum-based anticancer drugs"],"prefix":"10.1007","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4379-5283","authenticated-orcid":false,"given":"Maria S.","family":"Kamusheva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4450-7332","authenticated-orcid":false,"given":"Hristo P.","family":"Varbanov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,10]]},"reference":[{"key":"2172_CR1","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1038\/nm1087","volume":"10","author":"B Vogelstein","year":"2004","unstructured":"Vogelstein B, Kinzler KW (2004) Cancer genes and the pathways they control. Nat Med 10:789\u2013799. https:\/\/doi.org\/10.1038\/nm1087","journal-title":"Nat Med"},{"key":"2172_CR2","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Weinberg RA (2011) Hallmarks of cancer: The next generation. Cell 144:646\u2013674. https:\/\/doi.org\/10.1016\/j.cell.2011.02.013","journal-title":"Cell"},{"key":"2172_CR3","unstructured":"WHO (2025) Cancer. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/cancer. Accessed 15 May 2026"},{"key":"2172_CR4","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL et al (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 71:209\u2013249. https:\/\/doi.org\/10.3322\/caac.21660","journal-title":"CA Cancer J Clin"},{"key":"2172_CR5","doi-asserted-by":"publisher","first-page":"e2443198","DOI":"10.1001\/jamanetworkopen.2024.43198","volume":"7","author":"HM Bizuayehu","year":"2024","unstructured":"Bizuayehu HM, Ahmed KY, Kibret GD et al (2024) Global Disparities of Cancer and Its Projected Burden in 2050. JAMA Netw Open 7:e2443198. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.43198","journal-title":"JAMA Netw Open"},{"key":"2172_CR6","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1002\/cmdc.202100115","volume":"16","author":"D Gibson","year":"2021","unstructured":"Gibson D (2021) Pt(IV) Anticancer Prodrugs \u2013 A Tale of Mice and Men. ChemMedChem 16:2188\u20132191. https:\/\/doi.org\/10.1002\/cmdc.202100115","journal-title":"ChemMedChem"},{"key":"2172_CR7","first-page":"154","volume":"26","author":"E McCarthy","year":"2006","unstructured":"McCarthy E (2006) The toxins of William B. Coley and the treatment of bone and soft-tissue sarcomas. Iowa Orthop J 26:154\u2013158","journal-title":"Iowa Orthop J"},{"key":"2172_CR8","doi-asserted-by":"publisher","first-page":"133","DOI":"10.3109\/07388558509150782","volume":"3","author":"A Fujiwara","year":"1985","unstructured":"Fujiwara A, Hoshino T, Westley JW (1985) Anthracycline Antibiotics. Crit Rev Biotechnol 3:133\u2013157. https:\/\/doi.org\/10.3109\/07388558509150782","journal-title":"Crit Rev Biotechnol"},{"key":"2172_CR9","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.jamcollsurg.2010.10.018","volume":"212","author":"JE Fenn","year":"2011","unstructured":"Fenn JE, Udelsman R (2011) First use of intravenous chemotherapy cancer treatment: Rectifying the record. J Am Coll Surg 212:413\u2013417. https:\/\/doi.org\/10.1016\/j.jamcollsurg.2010.10.018","journal-title":"J Am Coll Surg"},{"key":"2172_CR10","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.ejphar.2014.07.025","volume":"740","author":"S Dasari","year":"2014","unstructured":"Dasari S, Bernard Tchounwou P (2014) Cisplatin in cancer therapy: Molecular mechanisms of action. Eur J Pharmacol 740:364\u2013378. https:\/\/doi.org\/10.1016\/j.ejphar.2014.07.025","journal-title":"Eur J Pharmacol"},{"key":"2172_CR11","doi-asserted-by":"publisher","first-page":"117894","DOI":"10.1016\/j.bmc.2024.117894","volume":"112","author":"D Sahoo","year":"2024","unstructured":"Sahoo D, Deb P, Basu T et al (2024) Advancements in platinum-based anticancer drug development: A comprehensive review of strategies, discoveries, and future perspectives. Bioorg Med Chem 112:117894. https:\/\/doi.org\/10.1016\/j.bmc.2024.117894","journal-title":"Bioorg Med Chem"},{"key":"2172_CR12","doi-asserted-by":"publisher","first-page":"3505","DOI":"10.1039\/c4dt02700k","volume":"44","author":"BJ Pages","year":"2015","unstructured":"Pages BJ, Ang DL, Wright EP, Aldrich-Wright JR (2015) Metal complex interactions with DNA. Dalton Trans 44:3505\u20133526. https:\/\/doi.org\/10.1039\/c4dt02700k","journal-title":"Dalton Trans"},{"key":"2172_CR13","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1038\/222385a0","volume":"222","author":"B Rosenberg","year":"1969","unstructured":"Rosenberg B, Vancamp L, Trosko J, Mansour V (1969) Platinum Compounds: a New Class of Potent Antitumour Agents. Nature 222:385\u2013386. https:\/\/doi.org\/10.1038\/222385a0","journal-title":"Nature"},{"key":"2172_CR14","unstructured":"National Center for Biotechnology Information (2025) PubChem Compound Summary for CID 5460033, Cisplatin. In: PubChem website. https:\/\/pubchem.ncbi.nlm.nih.gov. Accessed 15 May 2026"},{"key":"2172_CR15","doi-asserted-by":"publisher","first-page":"215439","DOI":"10.1016\/j.ccr.2023.215439","volume":"497","author":"PD O\u2019Dowd","year":"2023","unstructured":"O\u2019Dowd PD, Sutcliffe DF, Griffith DM (2023) Oxaliplatin and its derivatives \u2013 An overview. Coord Chem Rev 497:215439. https:\/\/doi.org\/10.1016\/j.ccr.2023.215439","journal-title":"Coord Chem Rev"},{"key":"2172_CR16","doi-asserted-by":"publisher","first-page":"102925","DOI":"10.1016\/j.bioorg.2019.102925","volume":"88","author":"S Ghosh","year":"2019","unstructured":"Ghosh S (2019) Cisplatin: The first metal based anticancer drug. Bioorg Chem 88:102925. https:\/\/doi.org\/10.1016\/j.bioorg.2019.102925","journal-title":"Bioorg Chem"},{"key":"2172_CR17","doi-asserted-by":"publisher","first-page":"4","DOI":"10.15252\/emmm.201607062","volume":"9","author":"J Nonnekens","year":"2017","unstructured":"Nonnekens J, Hoeijmakers JH (2017) After surviving cancer, what about late life effects of the cure? EMBO Mol Med 9:4\u20136. https:\/\/doi.org\/10.15252\/emmm.201607062","journal-title":"EMBO Mol Med"},{"key":"2172_CR18","doi-asserted-by":"publisher","first-page":"7","DOI":"10.15252\/emmm.201606230","volume":"9","author":"N Benkafadar","year":"2017","unstructured":"Benkafadar N, Menardo J, Bourien J et al (2017) Reversible p53 inhibition prevents cisplatin ototoxicity without blocking chemotherapeutic efficacy. EMBO Mol Med 9:7\u201326. https:\/\/doi.org\/10.15252\/emmm.201606230","journal-title":"EMBO Mol Med"},{"key":"2172_CR19","doi-asserted-by":"publisher","first-page":"118987","DOI":"10.1016\/j.ica.2019.118987","volume":"498","author":"H Calvert","year":"2019","unstructured":"Calvert H (2019) The clinical development of carboplatin \u2013 A personal perspective. Inorganica Chim Acta 498:118987. https:\/\/doi.org\/10.1016\/j.ica.2019.118987","journal-title":"Inorganica Chim Acta"},{"key":"2172_CR20","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1124\/pr.111.005637","volume":"64","author":"DW Shen","year":"2012","unstructured":"Shen DW, Pouliot LM, Hall MD, Gottesman MM (2012) Cisplatin resistance: A cellular self-defense mechanism resulting from multiple epigenetic and genetic changes. Pharmacol Rev 64:706\u2013721. https:\/\/doi.org\/10.1124\/pr.111.005637","journal-title":"Pharmacol Rev"},{"key":"2172_CR21","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1186\/s12967-021-02814-5","volume":"19","author":"S Gong","year":"2021","unstructured":"Gong S, Feng Y, Zeng Y et al (2021) Gut microbiota accelerates cisplatin-induced acute liver injury associated with robust inflammation and oxidative stress in mice. J Transl Med 19:147. https:\/\/doi.org\/10.1186\/s12967-021-02814-5","journal-title":"J Transl Med"},{"key":"2172_CR22","unstructured":"National Center for Biotechnology Information (2025) PubChem Compound Summary for CID 10339178, Carboplatin. In: National Center for Biotechnology Information. https:\/\/pubchem.ncbi.nlm.nih.gov. Accessed 15 May 2026"},{"key":"2172_CR23","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.1200\/JCO.1989.7.11.1748","volume":"7","author":"AH Calvert","year":"1989","unstructured":"Calvert AH, Newell DR, Gumbrell LA et al (1989) Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 7:1748\u20131756. https:\/\/doi.org\/10.1200\/JCO.1989.7.11.1748","journal-title":"J Clin Oncol"},{"key":"2172_CR24","unstructured":"National Center for Biotechnology Information (2025) PubChem Compound Summary for CID 9887054, Oxaliplatin. In: PubChem website. https:\/\/pubchem.ncbi.nlm.nih.gov. Accessed 15 May 2026"},{"key":"2172_CR25","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1039\/d3cb00087g","volume":"4","author":"Z Deng","year":"2023","unstructured":"Deng Z, Chen S, Liu G, Zhu G (2023) Unlocking the potential of platinum drugs: organelle-targeted small-molecule platinum complexes for improved anticancer performance. RSC Chem Biol 4:1003\u20131013. https:\/\/doi.org\/10.1039\/d3cb00087g","journal-title":"RSC Chem Biol"},{"key":"2172_CR26","doi-asserted-by":"publisher","first-page":"10835","DOI":"10.1039\/d2dt01875f","volume":"51","author":"S Alassadi","year":"2022","unstructured":"Alassadi S, Pisani MJ, Wheate NJ (2022) A chemical perspective on the clinical use of platinum-based anticancer drugs. Dalton Trans 51:10835\u201310846. https:\/\/doi.org\/10.1039\/d2dt01875f","journal-title":"Dalton Trans"},{"key":"2172_CR27","first-page":"455","volume":"34","author":"JJ Yu","year":"2014","unstructured":"Yu JJ, Yang XQ, Song QH, Mueller MD, Remick SC (2014) Dicycloplatin, a novel platinum analog in chemotherapy: synthesis of Chinese pre-clinical and clinical profile and emerging mechanistic studies. Anticancer Res 34:455\u2013463","journal-title":"Anticancer Res"},{"key":"2172_CR28","doi-asserted-by":"publisher","first-page":"67","DOI":"10.2147\/CMAR.S35785","volume":"5","author":"M Shimada","year":"2013","unstructured":"Shimada M, Itamochi H, Kigawa J (2013) Nedaplatin: a cisplatin derivative in cancer chemotherapy. Cancer Manag Res 5:67\u201376. https:\/\/doi.org\/10.2147\/CMAR.S35785","journal-title":"Cancer Manag Res"},{"key":"2172_CR29","unstructured":"Council RAD-AR (2016) Japan AQUPLA for Intravenous Injection 100\u00a0mg, Drug Information Sheet. https:\/\/www.rad-ar.or.jp\/siori\/english\/. Accessed 19 Aug 2026"},{"key":"2172_CR30","doi-asserted-by":"publisher","first-page":"12","DOI":"10.4143\/crt.2009.41.1.12","volume":"41","author":"KH Lee","year":"2009","unstructured":"Lee KH, Hyun MS, Kim H-K et al (2009) Randomized, Multicenter, Phase III Trial of Heptaplatin 1-hour Infusion and 5-Fluorouracil Combination Chemotherapy Comparing with Cisplatin and 5-Fluorouracil Combination Chemotherapy in Patients with Advanced Gastric Cancer. Cancer Res Treat 41:12. https:\/\/doi.org\/10.4143\/crt.2009.41.1.12","journal-title":"Cancer Res Treat"},{"key":"2172_CR31","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.7150\/jca.24557","volume":"9","author":"N Zhou","year":"2018","unstructured":"Zhou N, Zhao Y, Zhai L et al (2018) The Efficacy and Toxicity of Lobaplatin-contained Chemotherapy in Extensive-stage Small-cell Lung Cancer. J Cancer 9:2232\u20132236. https:\/\/doi.org\/10.7150\/jca.24557","journal-title":"J Cancer"},{"key":"2172_CR32","first-page":"523","volume":"77","author":"M Maeda","year":"1986","unstructured":"Maeda M, Uchida NA, Sasaki T (1986) Liposoluble platinum(II) complexes with antitumor activity. Jpn J Cancer Res 77:523\u2013525","journal-title":"Jpn J Cancer Res"},{"key":"2172_CR33","first-page":"271","volume":"37","author":"K Ikeda","year":"2010","unstructured":"Ikeda K, Okusaka T, Ikeda M, Morimoto M (2010) Transcatheter arterial chemoembolization with a lipophilic platinum complex SM-11355 (miriplatin hydrate): safety and efficacy in combination with embolizing agents. Gan Kagaku Ryoho 37:271\u2013275","journal-title":"Gan Kagaku Ryoho"},{"key":"2172_CR34","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/s00535-017-1374-6","volume":"53","author":"M Ikeda","year":"2018","unstructured":"Ikeda M, Kudo M, Aikata H et al (2018) Transarterial chemoembolization with miriplatin vs. epirubicin for unresectable hepatocellular carcinoma: a phase III randomized trial. J Gastroenterol 53:281\u2013290. https:\/\/doi.org\/10.1007\/s00535-017-1374-6","journal-title":"J Gastroenterol"},{"key":"2172_CR35","doi-asserted-by":"publisher","first-page":"5247","DOI":"10.21873\/anticanres.17865","volume":"45","author":"B-X Yan","year":"2025","unstructured":"Yan B-X, Liu X, Hao C et al (2025) Dicycloplatin, a Novel Analog of Cisplatin and Carboplatin, May Provide Therapeutic Advancement in Cancer Chemotherapy. Anticancer Res 45:5247\u20135254. https:\/\/doi.org\/10.21873\/anticanres.17865","journal-title":"Anticancer Res"},{"key":"2172_CR36","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1186\/s12885-026-15749-1","volume":"26","author":"Y Tian","year":"2026","unstructured":"Tian Y, Liu X, Liu X et al (2026) Accelerating cancer therapy review: a cross-sectional analysis of expedited approval in China, 2005\u20132021. BMC Cancer 26:390. https:\/\/doi.org\/10.1186\/s12885-026-15749-1","journal-title":"BMC Cancer"},{"key":"2172_CR37","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1021\/jm3016427","volume":"56","author":"HP Varbanov","year":"2013","unstructured":"Varbanov HP, Jakupec MA, Roller A et al (2013) Theoretical investigations and density functional theory based quantitative structure-activity relationships model for novel cytotoxic platinum(IV) complexes. J Med Chem 56:330\u2013344. https:\/\/doi.org\/10.1021\/jm3016427","journal-title":"J Med Chem"},{"key":"2172_CR38","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s41669-020-00220-z","volume":"5","author":"CM Cramer-van der Welle","year":"2021","unstructured":"Cramer-van der Welle CM, Peters BJM, Deenen MJ et al (2021) Trends in Drug Costs and Overall Survival in Patients with Metastatic Non-small Cell Lung Cancer in The Netherlands Diagnosed from 2008 Through 2014. Pharmacoecon Open 5:121\u2013127. https:\/\/doi.org\/10.1007\/s41669-020-00220-z","journal-title":"Pharmacoecon Open"},{"key":"2172_CR39","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.jval.2013.11.007","volume":"17","author":"DR Lairson","year":"2014","unstructured":"Lairson DR, Parikh RC, Cormier JN, Du XL (2014) Cost-utility analysis of platinum-based chemotherapy versus taxane and other regimens for ovarian cancer. Value Health 17:34\u201342. https:\/\/doi.org\/10.1016\/j.jval.2013.11.007","journal-title":"Value Health"},{"key":"2172_CR40","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1007\/s00432-018-2669-6","volume":"144","author":"E Armstrong-Gordon","year":"2018","unstructured":"Armstrong-Gordon E, Gnjidic D, McLachlan AJ et al (2018) Patterns of platinum drug use in an acute care setting: a retrospective study. J Cancer Res Clin Oncol 144:1561\u20131568. https:\/\/doi.org\/10.1007\/s00432-018-2669-6","journal-title":"J Cancer Res Clin Oncol"},{"key":"2172_CR41","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.ica.2019.04.023","volume":"492","author":"IS Um","year":"2019","unstructured":"Um IS, Armstrong-Gordon E, Moussa YE et al (2019) Platinum drugs in the Australian cancer chemotherapy healthcare setting: Is it worthwhile for chemists to continue to develop platinums? Inorganica Chim Acta 492:177\u2013181. https:\/\/doi.org\/10.1016\/j.ica.2019.04.023","journal-title":"Inorganica Chim Acta"},{"key":"2172_CR42","unstructured":"FDA (2024) National Drug Code Directory. NDC finished products search. https:\/\/dps.fda.gov\/ndc. Accessed 16 Mar 2026"},{"key":"2172_CR43","unstructured":"European Commission (2025) Public Health - Union Register of medicinal products. https:\/\/ec.europa.eu\/health\/documents\/community-register\/html\/index_en.htm Accessed 18 Aug 2026"},{"key":"2172_CR44","unstructured":"BASG (2024) Arzneispezialit\u00e4tenregister. https:\/\/medikamente.basg.gv.at\/de\/medicinal-products. Accessed 16 Mar 2026"},{"key":"2172_CR45","unstructured":"BDA (2024) Register of authorized medicines in Bulgaria. https:\/\/www.bda.bg\/bg\/. Accessed 16 Mar 2026"},{"key":"2172_CR46","unstructured":"European Society for Medical Oncology (ESMO) (2025) Clinical Practice Guidelines. https:\/\/www.esmo.org\/guidelines Accessed 15 May 2026"},{"key":"2172_CR47","unstructured":"National Comprehensive Cancer Network (NCCN) (2025) NCCN Clinical Practice Guidelines in Oncology. https:\/\/www.nccn.org\/guidelines\/category_1 Accessed 18 Aug 2026"},{"key":"2172_CR48","unstructured":"National Council on Prices and Reimbursement of Medicinal Products (NCPR) (2025) Pharmacotherapeutic guidelines in oncology. https:\/\/www.ncpr.bg\/images\/Naredbi\/2024\/Priturka_FTR_Onco-compressed.pdf Accessed 15 May 2026"},{"key":"2172_CR49","volume-title":"Chemotherapy Protocols 2023: Current Protocols and Targeted Therapies","author":"T K\u00fchr","year":"2023","unstructured":"K\u00fchr T, Thaler J, W\u00f6ll E (2023) Chemotherapy Protocols 2023: Current Protocols and Targeted Therapies, 24th edn. pdl, Innsbruck","edition":"24"},{"key":"2172_CR50","unstructured":"WHO (2013) International Classification of Diseases for Oncology. ICD-O Linearization. https:\/\/www.iccp-portal.org\/sites\/default\/files\/resources\/Intl%20Class%20of%20Diseases%20for%20Onco_2013.pdf. Accessed 15 May 2026"},{"key":"2172_CR51","volume-title":"OECD\/European Observatory on Health Systems and Policies. \u0417\u0434\u0440\u0430\u0432\u043d\u0438 \u043f\u0440\u043e\u0444\u0438\u043b\u0438 \u043d\u0430 \u0441\u0442\u0440\u0430\u043d\u0438\u0442\u0435: \u0411\u044a\u043b\u0433\u0430\u0440\u0438\u044f. State of Health in the EU","author":"European Commission","year":"2025","unstructured":"European Commission (2025) OECD\/European Observatory on Health Systems and Policies. \u0417\u0434\u0440\u0430\u0432\u043d\u0438 \u043f\u0440\u043e\u0444\u0438\u043b\u0438 \u043d\u0430 \u0441\u0442\u0440\u0430\u043d\u0438\u0442\u0435: \u0411\u044a\u043b\u0433\u0430\u0440\u0438\u044f. State of Health in the EU. OECD Publishing, Paris\/European Observatory on Health Systems and Policies, Brussels"},{"key":"2172_CR52","unstructured":"WHO (2025) International Statistical Classification of Diseases and Related Health Problems 10th Revision. https:\/\/icd.who.int\/browse10\/2019\/en. Accessed 15 May 2026"},{"key":"2172_CR53","unstructured":"EMA (2025) EU\/3\/07\/502 - orphan designation for treatment of small cell lung cancer. In: EMA. https:\/\/ec.europa.eu\/health\/documents\/community-register\/html\/o502.htm. Accessed 15 May 2026"},{"key":"2172_CR54","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.annonc.2023.11.016","volume":"35","author":"S Loibl","year":"2024","unstructured":"Loibl S, Andr\u00e9 F, Bachelot T et al (2024) Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol 35:159\u2013182. https:\/\/doi.org\/10.1016\/j.annonc.2023.11.016","journal-title":"Ann Oncol"},{"key":"2172_CR55","doi-asserted-by":"publisher","first-page":"103712","DOI":"10.1016\/j.breast.2024.103712","volume":"75","author":"SRE Mason","year":"2024","unstructured":"Mason SRE, Willson ML, Egger SJ et al (2024) Platinum chemotherapy for early triple-negative breast cancer. Breast 75:103712. https:\/\/doi.org\/10.1016\/j.breast.2024.103712","journal-title":"Breast"},{"key":"2172_CR56","unstructured":"National Statistical Institute, National Center of Public Health and Analyses (2024) Healthcare 2024 [in Bulgarian]. https:\/\/www.nsi.bg\/publications\/zdraveopazvane-2024-2270. Accessed 20 Aug 2026"},{"key":"2172_CR57","volume-title":"Bulgaria: Country Cancer Profile 2023. State of Health in the EU","author":"OECD, European Observatory on Health Systems and Policies","year":"2023","unstructured":"OECD, European Observatory on Health Systems and Policies (2023) Bulgaria: Country Cancer Profile 2023. State of Health in the EU. OECD Publishing, Paris"},{"key":"2172_CR58","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.critrevonc.2016.03.014","volume":"102","author":"GY Ho","year":"2016","unstructured":"Ho GY, Woodward N, Coward JIG (2016) Cisplatin versus carboplatin: Comparative review of therapeutic management in solid malignancies. Crit Rev Oncol Hematol 102:37\u201346. https:\/\/doi.org\/10.1016\/j.critrevonc.2016.03.014","journal-title":"Crit Rev Oncol Hematol"},{"key":"2172_CR59","unstructured":"Role of N-Acetylcysteine for Prevention of Cisplatin-induced Nephrotoxicity ID NCT06019520. In: ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT06019520?cond=Cisplatin%20Nephrotoxicity%26intr%3DAcetylcysteine%26limit%3D25%26page%3D1%26rank%3D3. Accessed 15 May 2026"},{"key":"2172_CR60","unstructured":"A Study of Topical Pirenzepine or Placebo in Oncology Patients With Chemotherapy Induced Peripheral Neuropathy ID NCT05488873. In: ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT05488873. Accessed 15 May 2026"},{"key":"2172_CR61","unstructured":"Protecting the Kidney\u2019s Proximal Tubules From Platinum-Based Chemotherapy Toxicity (DAPA-ARMOR) ID NCT07018622. In: ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT07018622. Accessed 15 May 2026"},{"key":"2172_CR62","unstructured":"SENS-401 to Prevent the Ototoxicity Induced by Cisplatin in Adult Subjects With a Neoplastic Disease (NOTOXIS). ID NCT05628233. In: ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT05628233 Accessed 15 May 2026"},{"key":"2172_CR63","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s13045-025-01698-y","volume":"18","author":"Y Chen","year":"2025","unstructured":"Chen Y, Jia K, Xie Y et al (2025) The current landscape of gastric cancer and gastroesophageal junction cancer diagnosis and treatment in China: a comprehensive nationwide cohort analysis. J Hematol Oncol 18:42. https:\/\/doi.org\/10.1186\/s13045-025-01698-y","journal-title":"J Hematol Oncol"},{"key":"2172_CR64","doi-asserted-by":"publisher","first-page":"e1721810","DOI":"10.1080\/2162402X.2020.1721810","volume":"9","author":"T Yamazaki","year":"2020","unstructured":"Yamazaki T, Buqu\u00e9 A, Ames TD, Galluzzi L (2020) PT-112 induces immunogenic cell death and synergizes with immune checkpoint blockers in mouse tumor models. Oncoimmunology 9:e1721810. https:\/\/doi.org\/10.1080\/2162402X.2020.1721810","journal-title":"Oncoimmunology"},{"key":"2172_CR65","unstructured":"PT-112 in Subjects With Thymoma and Thymic Carcinoma. ID NCT05104736. In: ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT05104736?viewType=Card&limit=10&sort=@relevance&intr=PT-112&rank=4#more-information. Accessed 12 Aug 2026"},{"key":"2172_CR66","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1007\/s12032-025-02812-3","volume":"42","author":"NA Yusoh","year":"2025","unstructured":"Yusoh NA, Ahmad H, Vallis KA, Gill MR (2025) Advances in platinum-based cancer therapy: overcoming platinum resistance through rational combinatorial strategies. Med Oncol 42:262. https:\/\/doi.org\/10.1007\/s12032-025-02812-3","journal-title":"Med Oncol"},{"key":"2172_CR67","doi-asserted-by":"publisher","first-page":"4517","DOI":"10.1021\/acs.jmedchem.6b01351","volume":"60","author":"DM Cheff","year":"2017","unstructured":"Cheff DM, Hall MD (2017) A Drug of Such Damned Nature.1 Challenges and Opportunities in Translational Platinum Drug Research. J Med Chem 60:4517\u20134532. https:\/\/doi.org\/10.1021\/acs.jmedchem.6b01351","journal-title":"J Med Chem"},{"key":"2172_CR68","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/S0006-3061(00)80249-5","volume":"2","author":"MJ Cleare","year":"1973","unstructured":"Cleare MJ, Hoeschele JD (1973) Studies on the Antitumor Activity of Group VIII Transition Metal Complexes. Part I. Platinum (II) Complexes. Bioinorg Chem 2:187\u2013210. https:\/\/doi.org\/10.1016\/S0006-3061(00)80249-5","journal-title":"Bioinorg Chem"},{"key":"2172_CR69","doi-asserted-by":"publisher","first-page":"3436","DOI":"10.1021\/acs.chemrev.5b00597","volume":"116","author":"TC Johnstone","year":"2016","unstructured":"Johnstone TC, Suntharalingam K, Lippard SJ (2016) The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs. Chem Rev 116:3436\u20133486. https:\/\/doi.org\/10.1021\/acs.chemrev.5b00597","journal-title":"Chem Rev"},{"key":"2172_CR70","doi-asserted-by":"publisher","first-page":"2146","DOI":"10.1021\/jm901693m","volume":"53","author":"M Skander","year":"2010","unstructured":"Skander M, Retailleau P, Bourri\u00e9 B et al (2010) N-Heterocyclic Carbene-Amine Pt(II) Complexes, a New Chemical Space for the Development of Platinum-Based Anticancer Drugs. J Med Chem 53:2146\u20132154. https:\/\/doi.org\/10.1021\/jm901693m","journal-title":"J Med Chem"},{"key":"2172_CR71","doi-asserted-by":"publisher","first-page":"6283","DOI":"10.1021\/acs.jmedchem.5b00896","volume":"58","author":"JK Muenzner","year":"2015","unstructured":"Muenzner JK, Rehm T, Biersack B et al (2015) Adjusting the DNA Interaction and Anticancer Activity of Pt(II) N-Heterocyclic Carbene Complexes by Steric Shielding of the Trans Leaving Group. J Med Chem 58:6283\u20136292. https:\/\/doi.org\/10.1021\/acs.jmedchem.5b00896","journal-title":"J Med Chem"},{"key":"2172_CR72","doi-asserted-by":"publisher","first-page":"106556","DOI":"10.1016\/j.phrs.2022.106556","volume":"187","author":"X Chang","year":"2023","unstructured":"Chang X, Bian M, Liu L et al (2023) Induction of immunogenic cell death by novel platinum-based anticancer agents. Pharmacol Res 187:106556. https:\/\/doi.org\/10.1016\/j.phrs.2022.106556","journal-title":"Pharmacol Res"},{"key":"2172_CR73","doi-asserted-by":"publisher","first-page":"293","DOI":"10.3390\/inorganics11070293","volume":"11","author":"P Kapitza","year":"2023","unstructured":"Kapitza P, Grabher P, Scherfler A et al (2023) Benzimidazole-Based NHC Metal Complexes as Anticancer Drug Candidates: Gold(I) vs. Platinum(II). Inorganics (Basel) 11:293. https:\/\/doi.org\/10.3390\/inorganics11070293","journal-title":"Inorganics (Basel)"},{"key":"2172_CR74","doi-asserted-by":"publisher","first-page":"117014","DOI":"10.1016\/j.ejmech.2024.117014","volume":"282","author":"L Tang","year":"2025","unstructured":"Tang L, Chang X, Shi J et al (2025) More than just DNA damage: Pt(\u0399\u0399)-NHC complexes derived from 4,5-diarylimidazoles augment immunogenic cell death. Eur J Med Chem 282:117014. https:\/\/doi.org\/10.1016\/j.ejmech.2024.117014","journal-title":"Eur J Med Chem"},{"key":"2172_CR75","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1002\/ejic.201900960","volume":"2020","author":"S Bellemin-Laponnaz","year":"2020","unstructured":"Bellemin-Laponnaz S (2020) N\u2010Heterocyclic Carbene Platinum Complexes: A Big Step Forward for Effective Antitumor Compounds. Eur J Inorg Chem 2020:10\u201320. https:\/\/doi.org\/10.1002\/ejic.201900960","journal-title":"Eur J Inorg Chem"},{"key":"2172_CR76","doi-asserted-by":"publisher","first-page":"214217","DOI":"10.1016\/j.ccr.2021.214217","volume":"449","author":"S Zhao","year":"2021","unstructured":"Zhao S, Yang Z, Jiang G et al (2021) An overview of anticancer platinum N-heterocyclic carbene complexes. Coord Chem Rev 449:214217. https:\/\/doi.org\/10.1016\/j.ccr.2021.214217","journal-title":"Coord Chem Rev"},{"key":"2172_CR77","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.jinorgbio.2018.11.008","volume":"191","author":"D Gibson","year":"2019","unstructured":"Gibson D (2019) Multi-action Pt(IV) anticancer agents; do we understand how they work? J Inorg Biochem 191:77\u201384. https:\/\/doi.org\/10.1016\/j.jinorgbio.2018.11.008","journal-title":"J Inorg Biochem"},{"key":"2172_CR78","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.ica.2019.04.025","volume":"492","author":"M Ravera","year":"2019","unstructured":"Ravera M, Gabano E, McGlinchey MJ, Osella D (2019) A view on multi-action Pt(IV) antitumor prodrugs. Inorganica Chim Acta 492:32\u201347. https:\/\/doi.org\/10.1016\/j.ica.2019.04.025","journal-title":"Inorganica Chim Acta"},{"key":"2172_CR79","doi-asserted-by":"publisher","first-page":"8167","DOI":"10.1039\/D1DT00214G","volume":"50","author":"S Harringer","year":"2021","unstructured":"Harringer S, Hejl M, Enyedy \u00c9A et al (2021) Multifunctional Pt(IV) prodrug candidates featuring the carboplatin core and deferoxamine. Dalton Trans 50:8167\u20138178. https:\/\/doi.org\/10.1039\/D1DT00214G","journal-title":"Dalton Trans"},{"key":"2172_CR80","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1021\/ja0432618","volume":"127","author":"WH Ang","year":"2005","unstructured":"Ang WH, Khalaila I, Allardyce CS et al (2005) Rational Design of Platinum(IV) Compounds to Overcome Glutathione-S-Transferase Mediated Drug Resistance. J Am Chem Soc 127:1382\u20131383. https:\/\/doi.org\/10.1021\/ja0432618","journal-title":"J Am Chem Soc"},{"key":"2172_CR81","doi-asserted-by":"publisher","first-page":"22199","DOI":"10.1073\/pnas.0912276106","volume":"106","author":"S Dhar","year":"2009","unstructured":"Dhar S, Lippard SJ (2009) Mitaplatin, a potent fusion of cisplatin and the orphan drug dichloroacetate. Proc Natl Acad Sci 106:22199\u201322204. https:\/\/doi.org\/10.1073\/pnas.0912276106","journal-title":"Proc Natl Acad Sci"},{"key":"2172_CR82","doi-asserted-by":"publisher","first-page":"111353","DOI":"10.1016\/j.jinorgbio.2020.111353","volume":"217","author":"D Gibson","year":"2021","unstructured":"Gibson D (2021) Platinum(IV) anticancer agents; are we en route to the holy grail or to a dead end? J Inorg Biochem 217:111353. https:\/\/doi.org\/10.1016\/j.jinorgbio.2020.111353","journal-title":"J Inorg Biochem"},{"key":"2172_CR83","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1039\/D1DT03886A","volume":"51","author":"M Ravera","year":"2022","unstructured":"Ravera M, Gabano E, McGlinchey MJ, Osella D (2022) Pt(IV) antitumor prodrugs: dogmas, paradigms, and realities. Dalton Trans 51:2121\u20132134. https:\/\/doi.org\/10.1039\/D1DT03886A","journal-title":"Dalton Trans"},{"key":"2172_CR84","doi-asserted-by":"publisher","first-page":"215578","DOI":"10.1016\/j.ccr.2023.215578","volume":"501","author":"P \u0160tarha","year":"2024","unstructured":"\u0160tarha P, K\u0159ikavov\u00e1 R (2024) Platinum(IV) and platinum(II) anticancer complexes with biologically active releasable ligands. Coord Chem Rev 501:215578. https:\/\/doi.org\/10.1016\/j.ccr.2023.215578","journal-title":"Coord Chem Rev"},{"key":"2172_CR85","doi-asserted-by":"publisher","first-page":"2729","DOI":"10.1007\/s11095-022-03317-8","volume":"39","author":"K Perera","year":"2022","unstructured":"Perera K, Nguyen DX, Wang D et al (2022) Biodegradable and Inherently Fluorescent pH-Responsive Nanoparticles for Cancer Drug Delivery. Pharm Res 39:2729\u20132743. https:\/\/doi.org\/10.1007\/s11095-022-03317-8","journal-title":"Pharm Res"},{"key":"2172_CR86","doi-asserted-by":"publisher","first-page":"e70019","DOI":"10.1002\/ddr.70019","volume":"85","author":"A Dubey","year":"2024","unstructured":"Dubey A, Raju F, Lobo CL et al (2024) Formulation and Characterization of RBCS Coated Carboplatin Loaded Nano-Liposomal Formulation for Managing Breast Cancer. Drug Dev Res 85:e70019. https:\/\/doi.org\/10.1002\/ddr.70019","journal-title":"Drug Dev Res"},{"key":"2172_CR87","doi-asserted-by":"publisher","first-page":"4719","DOI":"10.2147\/IJN.S449541","volume":"19","author":"Y Ma","year":"2024","unstructured":"Ma Y, Jiang T, Zhang R et al (2024) The Application of 2d Mxene Nanosheet-Based Thermosensitive Gel Delivery System Loaded with Cisplatin and Imiquimod for Lung Cancer. Int J Nanomed 19:4719\u20134733. https:\/\/doi.org\/10.2147\/IJN.S449541","journal-title":"Int J Nanomed"},{"key":"2172_CR88","doi-asserted-by":"publisher","first-page":"9337","DOI":"10.3390\/ijms25179337","volume":"25","author":"E Botter","year":"2024","unstructured":"Botter E, Caligiuri I, Rizzolio F et al (2024) Liposomal Formulations of Metallodrugs for Cancer Therapy. Int J Mol Sci 25:9337. https:\/\/doi.org\/10.3390\/ijms25179337","journal-title":"Int J Mol Sci"},{"key":"2172_CR89","doi-asserted-by":"publisher","first-page":"3013","DOI":"10.2147\/IJN.S362263","volume":"17","author":"H Tang","year":"2022","unstructured":"Tang H, Xie Y, Zhu M et al (2022) Estrone-Conjugated PEGylated Liposome Co-Loaded Paclitaxel and Carboplatin Improve Anti-Tumor Efficacy in Ovarian Cancer and Reduce Acute Toxicity of Chemo-Drugs. Int J Nanomed 17:3013\u20133041. https:\/\/doi.org\/10.2147\/IJN.S362263","journal-title":"Int J Nanomed"},{"key":"2172_CR90","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1007\/s13346-020-00867-5","volume":"11","author":"V Patel","year":"2021","unstructured":"Patel V, Lalani R, Vhora I et al (2021) Co-delivery of cisplatin and siRNA through hybrid nanocarrier platform for masking resistance to chemotherapy in lung cancer. Drug Deliv Transl Res 11:2052\u20132071. https:\/\/doi.org\/10.1007\/s13346-020-00867-5","journal-title":"Drug Deliv Transl Res"},{"key":"2172_CR91","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1089\/adt.2022.060","volume":"20","author":"S Jafari","year":"2022","unstructured":"Jafari S, Bakhshaei A, Eskandani M, Molavi O (2022) Silibinin-loaded nanostructured lipid carriers for growth inhibition of cisplatin-resistant ovarian cancer cells. Assay Drug Dev Technol 20:339\u2013348. https:\/\/doi.org\/10.1089\/adt.2022.060","journal-title":"Assay Drug Dev Technol"},{"key":"2172_CR92","doi-asserted-by":"publisher","first-page":"123686","DOI":"10.1016\/j.ijbiomac.2023.123686","volume":"235","author":"M Safari Sharafshadeh","year":"2023","unstructured":"Safari Sharafshadeh M, Tafvizi F, Khodarahmi P, Ehtesham S (2023) Preparation and physicochemical properties of cisplatin and doxorubicin encapsulated by niosome alginate nanocarrier for cancer therapy. Int J Biol Macromol 235:123686. https:\/\/doi.org\/10.1016\/j.ijbiomac.2023.123686","journal-title":"Int J Biol Macromol"},{"key":"2172_CR93","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.jconrel.2025.01.004","volume":"379","author":"X Wang","year":"2025","unstructured":"Wang X, Liu G, Pu X et al (2025) Combating cisplatin-resistant lung cancer using a coiled-coil lipopeptides modified membrane fused drug delivery system. J Controlled Release 379:45\u201358. https:\/\/doi.org\/10.1016\/j.jconrel.2025.01.004","journal-title":"J Controlled Release"},{"key":"2172_CR94","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/s12951-025-03206-3","volume":"23","author":"Z Lin","year":"2025","unstructured":"Lin Z, Li Y, Wu Z et al (2025) Eriodictyol-cisplatin coated nanomedicine synergistically promote osteosarcoma cells ferroptosis and chemosensitivity. J Nanobiotechnol 23:109. https:\/\/doi.org\/10.1186\/s12951-025-03206-3","journal-title":"J Nanobiotechnol"},{"key":"2172_CR95","doi-asserted-by":"publisher","first-page":"106993","DOI":"10.1016\/j.ejps.2024.106993","volume":"206","author":"N Gandhi","year":"2025","unstructured":"Gandhi N, Modi S, Soni S, Andey T (2025) Modular self-emulsifying drug delivery platform to enhance cellular uptake activity in triple-negative breast cancer. Eur J Pharm Sci 206:106993. https:\/\/doi.org\/10.1016\/j.ejps.2024.106993","journal-title":"Eur J Pharm Sci"},{"key":"2172_CR96","doi-asserted-by":"publisher","first-page":"114549","DOI":"10.1016\/j.colsurfb.2025.114549","volume":"250","author":"M Zhu","year":"2025","unstructured":"Zhu M, Xie Y, Li Z et al (2025) Antitumour and anti-angiogenesis efficacy of a multifunctional self-oxygenated active-targeting drug delivery system by encapsulating biological and chemotherapeutic drugs. Colloids Surf B Biointerfaces 250:114549. https:\/\/doi.org\/10.1016\/j.colsurfb.2025.114549","journal-title":"Colloids Surf B Biointerfaces"},{"key":"2172_CR97","doi-asserted-by":"publisher","first-page":"16548","DOI":"10.1021\/acs.langmuir.5c01941","volume":"41","author":"YP Wang","year":"2025","unstructured":"Wang YP, Ren XK, Sun QL et al (2025) Glycoluril polymers for codelivery in solid tumor therapy. Langmuir 41:16548\u201316556. https:\/\/doi.org\/10.1021\/acs.langmuir.5c01941","journal-title":"Langmuir"},{"key":"2172_CR98","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.jconrel.2023.04.011","volume":"357","author":"Z Gu","year":"2023","unstructured":"Gu Z, Hao Y, Schomann T et al (2023) Enhancing anti-tumor immunity through liposomal oxaliplatin and localized immunotherapy via STING activation. J Controlled Release 357:531\u2013544. https:\/\/doi.org\/10.1016\/j.jconrel.2023.04.011","journal-title":"J Controlled Release"},{"key":"2172_CR99","doi-asserted-by":"publisher","first-page":"113996","DOI":"10.1016\/j.colsurfb.2024.113996","volume":"241","author":"D Jiang","year":"2024","unstructured":"Jiang D, Nie H, Wang Z et al (2024) Developing oxaliplatin and IL-15 Co-carried gels as drug depots to enable triple-interlocked combination therapy for colorectal cancer. Colloids Surf B Biointerfaces 241:113996. https:\/\/doi.org\/10.1016\/j.colsurfb.2024.113996","journal-title":"Colloids Surf B Biointerfaces"},{"key":"2172_CR100","doi-asserted-by":"publisher","first-page":"2419033","DOI":"10.1002\/adma.202419033","volume":"37","author":"J Yang","year":"2025","unstructured":"Yang J, Su T, Wang Q et al (2025) Glucose Metabolism-Targeted Poly(amino acid) Nanoformulation of Oxaliplatin(IV)\u2010Aspirin Prodrug for Enhanced Chemo\u2010Immunotherapy. Adv Mater 37:2419033. https:\/\/doi.org\/10.1002\/adma.202419033","journal-title":"Adv Mater"},{"key":"2172_CR101","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1248\/cpb.c22-00099","volume":"70","author":"N Matsuo","year":"2022","unstructured":"Matsuo N, Ando H, Doi Y et al (2022) The challenge to deliver oxaliplatin (l-OHP) to solid tumors: development of liposomal l-OHP formulations. Chem Pharm Bull (Tokyo) 70:351\u2013358. https:\/\/doi.org\/10.1248\/cpb.c22-00099","journal-title":"Chem Pharm Bull (Tokyo)"},{"key":"2172_CR102","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.jconrel.2025.02.006","volume":"380","author":"H Liu","year":"2025","unstructured":"Liu H, Zou J, Li X et al (2025) Drug delivery for platinum therapeutics. J Controlled Release 380:503\u2013523. https:\/\/doi.org\/10.1016\/j.jconrel.2025.02.006","journal-title":"J Controlled Release"},{"key":"2172_CR103","doi-asserted-by":"publisher","first-page":"e70108","DOI":"10.1002\/ardp.70108","volume":"358","author":"A Scherfler","year":"2025","unstructured":"Scherfler A, Wurst K, Schwaiger S et al (2025) Loading of Dicarboxylatoplatinum(II)-NHC Complexes in Bacterial Ghosts as an Advanced Development in Cancer Therapy. Arch Pharm (Weinheim) 358:e70108. https:\/\/doi.org\/10.1002\/ardp.70108","journal-title":"Arch Pharm (Weinheim)"},{"key":"2172_CR104","doi-asserted-by":"publisher","first-page":"12234","DOI":"10.1021\/ic400538c","volume":"52","author":"TC Johnstone","year":"2013","unstructured":"Johnstone TC, Wilson JJ, Lippard SJ (2013) Monofunctional and higher-valent platinum anticancer agents. Inorg Chem 52:12234\u201312249. https:\/\/doi.org\/10.1021\/ic400538c","journal-title":"Inorg Chem"},{"key":"2172_CR105","doi-asserted-by":"publisher","first-page":"213640","DOI":"10.1016\/j.ccr.2020.213640","volume":"429","author":"C Jia","year":"2021","unstructured":"Jia C, Deacon GB, Zhang Y, Gao C (2021) Platinum(IV) antitumor complexes and their nano-drug delivery. Coord Chem Rev 429:213640. https:\/\/doi.org\/10.1016\/j.ccr.2020.213640","journal-title":"Coord Chem Rev"},{"key":"2172_CR106","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1007\/s12032-024-02598-w","volume":"42","author":"E Faderin","year":"2025","unstructured":"Faderin E, Iorkula TH, Aworinde OR et al (2025) Platinum nanoparticles in cancer therapy: chemotherapeutic enhancement and ROS generation. Med Oncol 42:42. https:\/\/doi.org\/10.1007\/s12032-024-02598-w","journal-title":"Med Oncol"},{"key":"2172_CR107","doi-asserted-by":"publisher","first-page":"97","DOI":"10.3390\/ijms24010097","volume":"24","author":"M Nunes","year":"2022","unstructured":"Nunes M, Duarte D, Vale N, Ricardo S (2022) The Antineoplastic Effect of Carboplatin Is Potentiated by Combination with Pitavastatin or Metformin in a Chemoresistant High-Grade Serous Carcinoma Cell Line. Int J Mol Sci 24:97. https:\/\/doi.org\/10.3390\/ijms24010097","journal-title":"Int J Mol Sci"},{"key":"2172_CR108","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.canlet.2021.09.029","volume":"522","author":"M Kwon","year":"2021","unstructured":"Kwon M, Nam GH, Jung H et al (2021) Statin in combination with cisplatin makes favorable tumor-immune microenvironment for immunotherapy of head and neck squamous cell carcinoma. Cancer Lett 522:198\u2013210. https:\/\/doi.org\/10.1016\/j.canlet.2021.09.029","journal-title":"Cancer Lett"},{"key":"2172_CR109","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.semcancer.2019.10.007","volume":"68","author":"V Shaw","year":"2021","unstructured":"Shaw V, Srivastava S, Srivastava SK (2021) Repurposing antipsychotics of the diphenylbutylpiperidine class for cancer therapy. Semin Cancer Biol 68:75\u201383. https:\/\/doi.org\/10.1016\/j.semcancer.2019.10.007","journal-title":"Semin Cancer Biol"},{"key":"2172_CR110","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3892\/ijmm.2024.5458","volume":"55","author":"YJ Cho","year":"2025","unstructured":"Cho YJ, Han BS, Ko S et al (2025) Repositioning of aripiprazole, an anti-psychotic drug, to sensitize the chemotherapy of pancreatic cancer. Int J Mol Med 55:17. https:\/\/doi.org\/10.3892\/ijmm.2024.5458","journal-title":"Int J Mol Med"},{"key":"2172_CR111","doi-asserted-by":"publisher","first-page":"3747","DOI":"10.7150\/ijbs.70679","volume":"18","author":"J Shi","year":"2022","unstructured":"Shi J, Zhou L, Huang HS et al (2022) Repurposing Oxiconazole against Colorectal Cancer via PRDX2-mediated Autophagy Arrest. Int J Biol Sci 18:3747\u20133761. https:\/\/doi.org\/10.7150\/ijbs.70679","journal-title":"Int J Biol Sci"},{"key":"2172_CR112","doi-asserted-by":"publisher","first-page":"15058","DOI":"10.1038\/s41598-022-18324-3","volume":"12","author":"LM Solern\u00f3","year":"2022","unstructured":"Solern\u00f3 LM, Sobol NT, Gottardo MF et al (2022) Propranolol blocks osteosarcoma cell cycle progression, inhibits angiogenesis and slows xenograft growth in combination with cisplatin-based chemotherapy. Sci Rep 12:15058. https:\/\/doi.org\/10.1038\/s41598-022-18324-3","journal-title":"Sci Rep"},{"key":"2172_CR113","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1002\/bab.2150","volume":"69","author":"E Zafar","year":"2022","unstructured":"Zafar E, Maqbool MF, Iqbal A et al (2022) A comprehensive review on anticancer mechanism of bazedoxifene. Biotechnol Appl Biochem 69:767\u2013782. https:\/\/doi.org\/10.1002\/bab.2150","journal-title":"Biotechnol Appl Biochem"},{"key":"2172_CR114","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1002\/ijc.35276","volume":"156","author":"H Branco","year":"2025","unstructured":"Branco H, Rodrigues CA, Oliveira J et al (2025) Preclinical studies on the antitumor and non-toxic effect of combining pirfenidone with vinorelbine and carboplatin in non-small cell lung cancer. Int J Cancer 156:1756\u20131769. https:\/\/doi.org\/10.1002\/ijc.35276","journal-title":"Int J Cancer"},{"key":"2172_CR115","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1158\/1535-7163.MCT-21-0613","volume":"21","author":"D Xu","year":"2022","unstructured":"Xu D, Cao Q, Wang L et al (2022) A Preclinical Study to Repurpose Spironolactone for Enhancing Chemotherapy Response in Bladder Cancer. Mol Cancer Ther 21:786\u2013798. https:\/\/doi.org\/10.1158\/1535-7163.MCT-21-0613","journal-title":"Mol Cancer Ther"},{"key":"2172_CR116","doi-asserted-by":"publisher","first-page":"7217","DOI":"10.1007\/s00432-023-04641-1","volume":"149","author":"KKW To","year":"2023","unstructured":"To KKW, Cheung KM, Cho WCS (2023) Repurposing of triamterene as a histone deacetylase inhibitor to overcome cisplatin resistance in lung cancer treatment. J Cancer Res Clin Oncol 149:7217\u20137234. https:\/\/doi.org\/10.1007\/s00432-023-04641-1","journal-title":"J Cancer Res Clin Oncol"},{"key":"2172_CR117","doi-asserted-by":"publisher","first-page":"e0309331","DOI":"10.1371\/journal.pone.0309331","volume":"19","author":"S Rodr\u00edguez-Enr\u00edquez","year":"2024","unstructured":"Rodr\u00edguez-Enr\u00edquez S, Robledo-Cadena DX, Pacheco-Vel\u00e1zquez SC et al (2024) Repurposing auranofin and meclofenamic acid as energy-metabolism inhibitors and anti-cancer drugs. PLoS ONE 19:e0309331. https:\/\/doi.org\/10.1371\/journal.pone.0309331","journal-title":"PLoS ONE"},{"key":"2172_CR118","doi-asserted-by":"publisher","first-page":"216509","DOI":"10.1016\/j.canlet.2023.216509","volume":"582","author":"J Namkaew","year":"2024","unstructured":"Namkaew J, Zhang J, Yamakawa N et al (2024) Repositioning of mifepristone as an integrated stress response activator to potentiate cisplatin efficacy in non-small cell lung cancer. Cancer Lett 582:216509. https:\/\/doi.org\/10.1016\/j.canlet.2023.216509","journal-title":"Cancer Lett"},{"key":"2172_CR119","doi-asserted-by":"publisher","first-page":"5802","DOI":"10.1080\/07391102.2022.2097312","volume":"41","author":"D Swami","year":"2023","unstructured":"Swami D, Mudaliar P, Bichu YS et al (2023) Synergistic combination of ritonavir and cisplatin as an efficacious therapy in human cervical cancer cells: a computational drug discovery and in vitro insight. J Biomol Struct Dyn 41:5802\u20135816. https:\/\/doi.org\/10.1080\/07391102.2022.2097312","journal-title":"J Biomol Struct Dyn"},{"key":"2172_CR120","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1186\/s13048-024-01509-x","volume":"17","author":"S-H Sue","year":"2024","unstructured":"Sue S-H, Tseng W-C, Wu Z-S et al (2024) The synergistic mechanisms of propofol with cisplatin or doxorubicin in human ovarian cancer cells. J Ovarian Res 17:187. https:\/\/doi.org\/10.1186\/s13048-024-01509-x","journal-title":"J Ovarian Res"},{"key":"2172_CR121","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.2174\/1871520623666230516161200","volume":"23","author":"R Du","year":"2023","unstructured":"Du R, Sun F, Li K et al (2023) Proteomics Analysis Revealed Smad3 as a Potential Target of the Synergistic Antitumor Activity of Disulfiram and Cisplatin in Ovarian Cancer. Anticancer Agents Med Chem 23:1754\u20131764. https:\/\/doi.org\/10.2174\/1871520623666230516161200","journal-title":"Anticancer Agents Med Chem"},{"key":"2172_CR122","doi-asserted-by":"publisher","first-page":"2404117","DOI":"10.1002\/adhm.202404117","volume":"14","author":"N Karimnia","year":"2025","unstructured":"Karimnia N, Wilson AL, Doran BR et al (2025) A Novel 3D High-Throughput Phenotypic Drug Screening Pipeline to Identify Drugs with Repurposing Potential for the Treatment of Ovarian Cancer. Adv Healthc Mater 14:2404117. https:\/\/doi.org\/10.1002\/adhm.202404117","journal-title":"Adv Healthc Mater"},{"key":"2172_CR123","doi-asserted-by":"publisher","first-page":"2790","DOI":"10.3390\/nu15122790","volume":"15","author":"N-R Han","year":"2023","unstructured":"Han N-R, Park H-J, Ko S-G, Moon P-D (2023) The Mixture of Natural Products SH003 Exerts Anti-Melanoma Effects through the Modulation of PD-L1 in B16F10 Cells. Nutrients 15:2790. https:\/\/doi.org\/10.3390\/nu15122790","journal-title":"Nutrients"},{"key":"2172_CR124","doi-asserted-by":"publisher","first-page":"e0211268","DOI":"10.1371\/journal.pone.0211268","volume":"14","author":"HP Varbanov","year":"2019","unstructured":"Varbanov HP, Kuttler F, Banfi D et al (2019) Screening-based approach to discover effective platinum-based chemotherapies for cancers with poor prognosis. PLoS ONE 14:e0211268. https:\/\/doi.org\/10.1371\/journal.pone.0211268","journal-title":"PLoS ONE"},{"key":"2172_CR125","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1681\/ASN.0000000000000261","volume":"35","author":"CK Pushpan","year":"2024","unstructured":"Pushpan CK, Kresock DF, Ingersoll MA et al (2024) Repurposing AZD5438 and Dabrafenib for Cisplatin-Induced AKI. J Am Soc Nephrol 35:22\u201340. https:\/\/doi.org\/10.1681\/ASN.0000000000000261","journal-title":"J Am Soc Nephrol"},{"key":"2172_CR126","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1016\/j.kint.2020.10.041","volume":"99","author":"H Hamano","year":"2021","unstructured":"Hamano H, Ikeda Y, Goda M et al (2021) Diphenhydramine may be a preventive medicine against cisplatin-induced kidney toxicity. Kidney Int 99:885\u2013899. https:\/\/doi.org\/10.1016\/j.kint.2020.10.041","journal-title":"Kidney Int"},{"key":"2172_CR127","doi-asserted-by":"publisher","unstructured":"Abass SA, Elgazar AA, El-kholy SS et al (2024) Unraveling the Nephroprotective Potential of Papaverine against Cisplatin Toxicity through Mitigating Oxidative Stress and Inflammation: Insights from In Silico, In Vitro, and In Vivo Investigations. Molecules 29:1927. https:\/\/doi.org\/10.3390\/molecules29091927","DOI":"10.3390\/molecules29091927"},{"key":"2172_CR128","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1093\/toxsci\/kfaf053","volume":"206","author":"JY Akakpo","year":"2025","unstructured":"Akakpo JY, Abbott E, Woolbright BL et al (2025) 4-Methylpyrazole-mediated inhibition of cytochrome P450 2E1 protects renal epithelial cells, but not bladder cancer cells, from cisplatin toxicity. Toxicol Sci 206:4\u201318. https:\/\/doi.org\/10.1093\/toxsci\/kfaf053","journal-title":"Toxicol Sci"},{"key":"2172_CR129","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2023\/9595201","volume":"2023","author":"S Shi","year":"2023","unstructured":"Shi S, Luo H, Ji Y et al (2023) Repurposing Dihydroartemisinin to Combat Oral Squamous Cell Carcinoma, Associated with Mitochondrial Dysfunction and Oxidative Stress. Oxid Med Cell Longev 2023:1\u201325. https:\/\/doi.org\/10.1155\/2023\/9595201","journal-title":"Oxid Med Cell Longev"},{"key":"2172_CR130","doi-asserted-by":"publisher","first-page":"112744","DOI":"10.1016\/j.biopha.2022.112744","volume":"148","author":"Y Zamami","year":"2022","unstructured":"Zamami Y, Niimura T, Kawashiri T et al (2022) Identification of prophylactic drugs for oxaliplatin-induced peripheral neuropathy using big data. Biomed Pharmacother 148:112744. https:\/\/doi.org\/10.1016\/j.biopha.2022.112744","journal-title":"Biomed Pharmacother"},{"key":"2172_CR131","doi-asserted-by":"publisher","first-page":"5613","DOI":"10.21873\/anticanres.16764","volume":"43","author":"A Kobayashi","year":"2023","unstructured":"Kobayashi A, Ikemura K, Wakai E et al (2023) Proton Pump Inhibitors Ameliorate Oxaliplatin-induced Peripheral Neuropathy: Retrospective Analysis of Two Real-world Clinical Databases. Anticancer Res 43:5613\u20135620. https:\/\/doi.org\/10.21873\/anticanres.16764","journal-title":"Anticancer Res"},{"key":"2172_CR132","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1158\/2767-9764.CRC-22-0128","volume":"2","author":"A van der Westhuizen","year":"2022","unstructured":"van der Westhuizen A, Lyle M, Graves MC et al (2022) Repurposing azacitidine and carboplatin to prime immune checkpoint blockade-resistant melanoma for anti-PD-L1 rechallenge. Cancer Res Commun 2:814\u2013826. https:\/\/doi.org\/10.1158\/2767-9764.CRC-22-0128","journal-title":"Cancer Res Commun"},{"key":"2172_CR133","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1089\/omi.2023.0163","volume":"28","author":"S Giridhara Prema","year":"2024","unstructured":"Giridhara Prema S, Chandrasekaran J, Kanekar S et al (2024) Cisplatin and Procaterol Combination in Gastric Cancer? Targeting Checkpoint Kinase 1 for Cancer Drug Discovery and Repurposing by an Integrated Computational and Experimental Approach. OMICS 28:8\u201323. https:\/\/doi.org\/10.1089\/omi.2023.0163","journal-title":"OMICS"},{"key":"2172_CR134","doi-asserted-by":"publisher","first-page":"2305308","DOI":"10.1080\/07853890.2024.2305308","volume":"55","author":"M Ahmed","year":"2023","unstructured":"Ahmed M, Semreen AM, Giddey AD et al (2023) Proteomic and metabolomic signatures of U87 glioblastoma cells treated with cisplatin and\/or paclitaxel. Ann Med 55:2305308. https:\/\/doi.org\/10.1080\/07853890.2024.2305308","journal-title":"Ann Med"},{"key":"2172_CR135","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1007\/s12017-025-08847-z","volume":"27","author":"K Temiz","year":"2025","unstructured":"Temiz K, Gul A, Gov E (2025) 5-Repurposed Drug Candidates Identified in Motor Neurons and Muscle Tissues with Amyotrophic Lateral Sclerosis by Network Biology and Machine Learning Based on Gene Expression. Neuromolecular Med 27:24. https:\/\/doi.org\/10.1007\/s12017-025-08847-z","journal-title":"Neuromolecular Med"},{"key":"2172_CR136","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s12896-021-00680-z","volume":"21","author":"M Adhami","year":"2021","unstructured":"Adhami M, Sadeghi B, Rezapour A et al (2021) Repurposing novel therapeutic candidate drugs for coronavirus disease-19 based on protein-protein interaction network analysis. BMC Biotechnol 21:22. https:\/\/doi.org\/10.1186\/s12896-021-00680-z","journal-title":"BMC Biotechnol"},{"key":"2172_CR137","doi-asserted-by":"publisher","first-page":"21872","DOI":"10.1038\/s41598-021-01410-3","volume":"11","author":"H MotieGhader","year":"2021","unstructured":"MotieGhader H, Safavi E, Rezapour A et al (2021) Drug repurposing for coronavirus (SARS-CoV-2) based on gene co-expression network analysis. Sci Rep 11:21872. https:\/\/doi.org\/10.1038\/s41598-021-01410-3","journal-title":"Sci Rep"},{"key":"2172_CR138","doi-asserted-by":"publisher","first-page":"104640","DOI":"10.1016\/j.compbiomed.2021.104640","volume":"135","author":"SA Muhammad","year":"2021","unstructured":"Muhammad SA, Qousain Naqvi ST, Nguyen T et al (2021) Cisplatin\u2019s potential for type 2 diabetes repositioning by inhibiting CDKN1A, FAS, and SESN1. Comput Biol Med 135:104640. https:\/\/doi.org\/10.1016\/j.compbiomed.2021.104640","journal-title":"Comput Biol Med"},{"key":"2172_CR139","doi-asserted-by":"publisher","first-page":"602958","DOI":"10.3389\/fcimb.2020.602958","volume":"10","author":"C Lettl","year":"2020","unstructured":"Lettl C, Schindele F, Testolin G et al (2020) Inhibition of Type IV Secretion Activity and Growth of Helicobacter pylori by Cisplatin and Other Platinum Complexes. Front Cell Infect Microbiol 10:602958. https:\/\/doi.org\/10.3389\/fcimb.2020.602958","journal-title":"Front Cell Infect Microbiol"},{"key":"2172_CR140","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1021\/acsinfecdis.3c00686","volume":"10","author":"C Guo","year":"2024","unstructured":"Guo C, Wang KKA, Nolan EM (2024) Investigation of Siderophore-Platinum(IV) Conjugates Reveals Differing Antibacterial Activity and DNA Damage Depending on the Platinum Cargo. ACS Infect Dis 10:1250\u20131266. https:\/\/doi.org\/10.1021\/acsinfecdis.3c00686","journal-title":"ACS Infect Dis"},{"key":"2172_CR141","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.1039\/D2DT03365H","volume":"52","author":"M Kaur","year":"2023","unstructured":"Kaur M, Thakare R, Bhattacherya A et al (2023) Antimicrobial efficacy of a hemilabile Pt(II)\u2013NHC compound against drug-resistant S. aureus and Enterococcus. Dalton Trans 52:1876\u20131884. https:\/\/doi.org\/10.1039\/D2DT03365H","journal-title":"Dalton Trans"},{"key":"2172_CR142","doi-asserted-by":"publisher","first-page":"2627","DOI":"10.1039\/C9SC06460E","volume":"11","author":"A Frei","year":"2020","unstructured":"Frei A, Zuegg J, Elliott AG et al (2020) Metal complexes as a promising source for new antibiotics. Chem Sci 11:2627\u20132639. https:\/\/doi.org\/10.1039\/C9SC06460E","journal-title":"Chem Sci"},{"key":"2172_CR143","doi-asserted-by":"publisher","first-page":"118216","DOI":"10.1016\/j.ejmech.2025.118216","volume":"301","author":"M Kraihammer","year":"2026","unstructured":"Kraihammer M, Varbanov HP, Dvo\u0159\u00e1kov\u00e1 Bendov\u00e1 K et al (2026) Repurposing carboplatin-based Pt(IV)-deferoxamine conjugates for infection theranostics. Eur J Med Chem 301:118216. https:\/\/doi.org\/10.1016\/j.ejmech.2025.118216","journal-title":"Eur J Med Chem"}],"container-title":["JBIC Journal of Biological Inorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00775-026-02172-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00775-026-02172-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00775-026-02172-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T19:02:58Z","timestamp":1791399778000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00775-026-02172-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,10]]},"references-count":143,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["2172"],"URL":"https:\/\/doi.org\/10.1007\/s00775-026-02172-x","relation":{},"ISSN":["1432-1327"],"issn-type":[{"value":"1432-1327","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,10]]},"assertion":[{"value":"20 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted following all applicable ethical guidelines.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent to publish","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":5,"name":"Ethics","label":"Clinical trial number","group":{"name":"EthicsHeading","label":"Declarations"}}]}}